Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) Q3 2025 Earnings Call Transcript November 12, 2025 Atea Pharmaceuticals, Inc.
The U.S. Food and Drug Administration announced it is taking action to approve new labeling submitted by the company that includes the addition of ...
(NAPSI)—When winter weather comes, the Outdoor Power Equipment Institute (OPEI) encourages home and business owners to review ...
The U.S. Food and Drug Administration said on Friday it approved new labeling for Sarepta Therapeutics' gene therapy Elevidys ...
The Food and Drug Administration is adding a new warning to a gene therapy linked to two patient deaths earlier this year.
A gene therapy for Duchenne muscular dystrophy caused complications to the liver, prompting a review of its use for younger patients.
The agency is cautioning patients about the risk of serious, possibly fatal, liver injuries and has limited the gene therapy's use to ambulatory patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback